ID

22136

Descrizione

Study part: Day 0 EORTC. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"

Keywords

versioni (2)

1. 20/05/17 20/05/17 -
2. 28/05/17 28/05/17 -

Titolare del copyright

Roche

Caricato su

20 maggio 2017

DOI

Per favore, per richiedere un accesso.

Licenza